HKEX Stock Code: 01093
English
|
繁體
|
简体
Home
About Us
Products
News
Competence
Investor Relations
Contact Us
Corporate Profile
Corporate Information
Corporate Culture
Board of Directors
Corporate Governance
Products Overview
Finished Drugs
Bulk Drugs
Press Releases
Strategies
Quality
Research and Development
IR Overview
Financial Reports
CSR Reports
Announcements & Notices
Returns on Share Capital
Circulars
Presentations
Documents on Display
Shareholder Services
Notice(s) of Replacement
of Lost Share Certificates
Financial Calendar
Financial Summary
IR Contacts
Investor Relations
IR Overview
Financial Reports
CSR Reports
Announcements & Notices
Returns on Share Capital
Circulars
Presentations
Documents on Display
Shareholder Services
Notice(s) of Replacement of Lost Share Certificates
Financial Calendar
Financial Summary
IR Contacts
Home
>
Investor Relations
> Announcements & Notices
Announcements & Notices
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
Mar
25
VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE INJECTION FOR OVERWEIGHT/OBESITY INDICATION OBTAINS CLINICAL TRIAL APPROVAL
Mar
22
VOLUNTARY ANNOUNCEMENT - DAPAGLIFLOZIN TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Mar
20
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL
Mar
20
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Mar
20
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Mar
18
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL
Mar
14
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2023
Mar
08
DATE OF BOARD MEETING
Feb
05
VOLUNTARY ANNOUNCEMENT - INDICATION FOR ACUTE ISCHEMIC STROKE OF MINGFULE (RECOMBINANT HUMAN TNK TISSUE-TYPE PLASMINOGEN ACTIVATOR FOR INJECTION) OBTAINS MARKETING APPROVAL
Jan
24
KEY FINANCIAL INFORMATION OF A SUBSIDIARY FOR THE YEAR ENDED 31 DECEMBER 2023
Jan
15
VOLUNTARY ANNOUNCEMENT - BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Please download the latest "
Acrobat Reader
" to view the PDF.